MedDataX Logo

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

NCT ID: NCT03475706

Last Updated: 2020-03-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

438 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-19

Study Completion Date

2019-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of solabegron immediate release low dose or high dose tablets, compared to matched placebo, administered twice daily for 12 weeks to adult female subjects with overactive bladder symptoms (frequency, urgency, and predominantly urgency incontinence) for at least 6 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

NCT03594058

Overactive Bladder
COMPLETED PHASE2

Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms

NCT00343486

Overactive Bladder
COMPLETED PHASE2

Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects

NCT02938507

Healthy Subjects, Overactive Bladder
COMPLETED PHASE1

A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder

NCT00501267

Overactive Bladder
COMPLETED PHASE1

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder

NCT01340027

Urologic Diseases Urinary Bladder Diseases Urological Manifestations +2 more
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Bladder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Eligible female subjects (N=406) with symptoms of overactive bladder for at least 6 months will enter a 14-day single-blind Run-in Period. Subjects (N=375) who meet prespecified criteria based on data entered into an electronic diary over 3 days will be randomized 1:1:1 (125 subjects per arm) to receive solabegron immediate release tablets, low dose or high dose, or matching placebo.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
Sponsor representatives Site monitors Data managers Statisticians

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Solabegron immediate release tablets low dose

Group Type EXPERIMENTAL

Solabegron immediate release tablets, low dose

Intervention Type DRUG

twice daily for 12 weeks.

Solabegron immediate release tablets high dose

Group Type EXPERIMENTAL

Solabegron immediate release tablets, high dose

Intervention Type DRUG

twice daily for 12 weeks.

Placebo Comparator

Group Type PLACEBO_COMPARATOR

Matching Placebo

Intervention Type DRUG

twice daily for 12 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Solabegron immediate release tablets, low dose

twice daily for 12 weeks.

Intervention Type DRUG

Solabegron immediate release tablets, high dose

twice daily for 12 weeks.

Intervention Type DRUG

Matching Placebo

twice daily for 12 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult female subjects 18 to 80 years of age, with a ≥ 6-month history of symptoms of overactive bladder including: frequency, urgency, and urgency urinary incontinence. Subjects must provide written informed consent and either be of non-childbearing potential or of childbearing potential meeting specific criteria (e.g., negative pregnancy test, sexual inactivity, acceptable methods of birth control, and use of hormonal contraceptives).

Exclusion Criteria

* Subjects must have no history of pelvic or bladder disease, e.g., Grade 3/4 uterine prolapse, urogenital malignancy within the past 2 years, surgery for stress incontinence or pelvic prolapse repair within the past 6 months, or bladder injections with botulinum toxin at any time.
* Diabetes insipidus or poorly controlled Type 1 or Type 2 diabetes mellitus
* Cardiac conditions: prior cardiovascular events or procedures within 6 months of screening; congestive heart failure; abnormal ECG findings, including ECG QT correction interval (QTc) \> 470 msec at the Screening Visit; systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥100mmHg, or heart rate \> 100 beats per minute.
* Abnormal tests of liver function
* History of prior infection due to HIV or hepatitis B or hepatitis C virus
* Allergy or hypersensitivity to solabegron or mirabegron
* Women of childbearing potential: breastfeeding, pregnant, or actively trying to become pregnant
* Participation in a trial of an investigational or marketed drug ≤ 30 days prior to the Screening Visit or in any clinical trial of an investigational drug that may affect urinary function within 3 months prior to Screening Visit.
* Inability to read, understand, or complete study-related materials.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Velicept Therapeutics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Velicept Investigative Site - Birmingham

Birmingham, Alabama, United States

Site Status

Velicept Investigative Site - Gulf Shores

Gulf Shores, Alabama, United States

Site Status

Velicept Investigative Site - Mobile

Mobile, Alabama, United States

Site Status

Velicept Investigative Site - Tempe

Tempe, Arizona, United States

Site Status

Velicept Investigative Site - Tucson

Tucson, Arizona, United States

Site Status

Velicept Investigative Site - Little Rock

Little Rock, Arkansas, United States

Site Status

Velicept Investigative Site - Anaheim

Anaheim, California, United States

Site Status

Velicept Investigative Site - Arcadia

Arcadia, California, United States

Site Status

Velicept Investigative Site - Canoga Park

Canoga Park, California, United States

Site Status

Velicept Investigative Site - Huntington Beach

Huntington Beach, California, United States

Site Status

Velicept Investigative Site - Los Alamitos

Los Alamitos, California, United States

Site Status

Velicept Investigative Site - Los Angeles

Los Angeles, California, United States

Site Status

Velicept Investigative Site - Norco

Norco, California, United States

Site Status

Velicept Investigative Site - Sacramento

Sacramento, California, United States

Site Status

Velicept Investigative Site - San Diego

San Diego, California, United States

Site Status

Velicept Investigative Site - San Diego

San Diego, California, United States

Site Status

Velicept Investigative Site - San Marcos

San Marcos, California, United States

Site Status

Velicept Investigative Site - Thousand Oaks

Thousand Oaks, California, United States

Site Status

Velicept Investigative Site - Denver

Denver, Colorado, United States

Site Status

Velicept Investigative Site - Waterbury

Waterbury, Connecticut, United States

Site Status

Velicept Investigative Site - Clearwater

Clearwater, Florida, United States

Site Status

Velicept Investigative Site - Deland

DeLand, Florida, United States

Site Status

Velicept Investigative Site - Doral

Doral, Florida, United States

Site Status

Velicept Investigative Site - Jupiter

Jupiter, Florida, United States

Site Status

Velicept Investigative Site - Lake City

Lake City, Florida, United States

Site Status

Velicept Investigative Site - Miami

Miami, Florida, United States

Site Status

Velicept Investigative Site - Miami

Miami, Florida, United States

Site Status

Velicept Investigative Site - Miami

Miami, Florida, United States

Site Status

Velicept Investigative Site - Ponte Vedra

Ponte Vedra, Florida, United States

Site Status

Velicept Investigative Site - Port St Lucie

Port Saint Lucie, Florida, United States

Site Status

Velicept Investigative Site - West Palm Beach

West Palm Beach, Florida, United States

Site Status

Velicept Investigative Site - Winter Haven

Winter Haven, Florida, United States

Site Status

Velicept Investigative Site - Marietta

Marietta, Georgia, United States

Site Status

Velicept Investigative Site - Blackfoot

Blackfoot, Idaho, United States

Site Status

Velicept Investigative Site - Meridian

Meridian, Idaho, United States

Site Status

Velicept Investigative Site - Wauconda

Wauconda, Illinois, United States

Site Status

Velicept Investigative Site - Elwood

Elwood, Indiana, United States

Site Status

Velicept Investigative Site - Evansville

Evansville, Indiana, United States

Site Status

Velicept Investigative Site - Newton

Newton, Kansas, United States

Site Status

Velicept Investigative Site - Louisville

Louisville, Kentucky, United States

Site Status

Velicept Investigative Site - Metairie

Metairie, Louisiana, United States

Site Status

Velicept Investigative Site - New Orleans

New Orleans, Louisiana, United States

Site Status

Velicept Investigative Site - Shreveport

Shreveport, Louisiana, United States

Site Status

Velicept Investigative Site - Boston

Boston, Massachusetts, United States

Site Status

Velicept Investigative Site - New Bedford

New Bedford, Massachusetts, United States

Site Status

Velicept Investigative Site - North Attleborro

North Attleboro, Massachusetts, United States

Site Status

Velicept Investigative Site - Watertown

Watertown, Massachusetts, United States

Site Status

Velicept Investigative Site - Kalamazoo

Kalamazoo, Michigan, United States

Site Status

Velicept Investigative Site - St. Louis

St Louis, Missouri, United States

Site Status

Velicept Investigative Site - Omaha

Omaha, Nebraska, United States

Site Status

Velicept Investigative Site - Las Vegas

Las Vegas, Nevada, United States

Site Status

Velicept Investigative Site - Brick

Brick, New Jersey, United States

Site Status

Velicept Investigative Site - Vorhees

Voorhees Township, New Jersey, United States

Site Status

Velicept Investigative Site - Albuquerque

Albuquerque, New Mexico, United States

Site Status

Velicept Investigative Site - New York

New York, New York, United States

Site Status

Velicept Investigative Site - Williamsville

Williamsville, New York, United States

Site Status

Velicept Investigative Site - Charlotte

Charlotte, North Carolina, United States

Site Status

Velicept Investigative Site - Wilmington

Wilmington, North Carolina, United States

Site Status

Velicept Investigative Site - Winston-Salem

Winston-Salem, North Carolina, United States

Site Status

Velicept Investigative Site - Cincinnati

Cincinnati, Ohio, United States

Site Status

Velicept Investigative Site - Cleveland

Cleveland, Ohio, United States

Site Status

Velicept Investigative Site - Columbus

Columbus, Ohio, United States

Site Status

Velicept Investigative Site - Marion

Marion, Ohio, United States

Site Status

Velicept Investigative Site - Middleburg Heights

Middleburg Heights, Ohio, United States

Site Status

Velicept Investigative Site - Warwick

Warwick, Rhode Island, United States

Site Status

Velicept Investigative Site - Mt. Pleasant

Mt. Pleasant, South Carolina, United States

Site Status

Velicept Investigative Site - Myrtle Beach

Myrtle Beach, South Carolina, United States

Site Status

Velicept Investigative Site - Jackson

Jackson, Tennessee, United States

Site Status

Velicept Investigative Site - Knoxville

Knoxville, Tennessee, United States

Site Status

Velicept Investigative Site - Nashville

Nashville, Tennessee, United States

Site Status

Velicept Investigative Site - Austin

Austin, Texas, United States

Site Status

Velicept Investigative Site - Beaumont

Beaumont, Texas, United States

Site Status

Velicept Investigative Site - Lampasas

Lampasas, Texas, United States

Site Status

Velicept Investigative Site - Longview

Longview, Texas, United States

Site Status

Velicept Investigative Site - San Antonio

San Antonio, Texas, United States

Site Status

Velicept Investigative Site - San Antonio

San Antonio, Texas, United States

Site Status

Velicept Investigative Site - San Antonio

San Antonio, Texas, United States

Site Status

Velicept Investigative Site - Clinton

Clinton, Utah, United States

Site Status

Velicept Investigative Site - Salt Lake City

Salt Lake City, Utah, United States

Site Status

Velicept Investigative Site - Salt Lake City

Salt Lake City, Utah, United States

Site Status

Velicept Investigative Site - St. George

St. George, Utah, United States

Site Status

Velicept Investigative Site - West Jordan

West Jordan, Utah, United States

Site Status

Velicept Investigative Site - Newport News

Newport News, Virginia, United States

Site Status

Velicept Investigative Site - Norfolk

Norfolk, Virginia, United States

Site Status

Velicept Investigative Site - Tacoma

Tacoma, Washington, United States

Site Status

Velicept Investigative Site - Kenosha

Kenosha, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the beta3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol. 2012 Nov;62(5):834-40. doi: 10.1016/j.eururo.2012.05.053. Epub 2012 Jun 5.

Reference Type BACKGROUND
PMID: 22695239 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VEL-2002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
NCT02045862 COMPLETED PHASE3
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
NCT01972841 COMPLETED PHASE3
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NCT00321477 COMPLETED PHASE2
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
NCT01638000 COMPLETED PHASE3
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
NCT02216214 COMPLETED PHASE4
Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder
NCT00196404 COMPLETED PHASE2
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00662909 COMPLETED PHASE3
Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder
NCT00773552 WITHDRAWN PHASE4
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00912964 COMPLETED PHASE3
Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes
NCT02540707 COMPLETED PHASE4
A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder
NCT03566134 COMPLETED PHASE2
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00689104 COMPLETED PHASE3
SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
NCT00507169 COMPLETED PHASE2
A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder
NCT05282069 COMPLETED PHASE3
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00688688 COMPLETED PHASE3
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
NCT00350636 COMPLETED PHASE3
A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
NCT02386072 COMPLETED
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
NCT01908829 COMPLETED PHASE3
Reproducibility Study of OABSS and Its Response to Treatment
NCT02667470 COMPLETED PHASE4
A Study to Estimate the Efficacy and Safety of Solifenacin in Female With Stress Urinary Incontinence and Urgency Urinary Incontinence
NCT01505439 COMPLETED PHASE4
Feasibility of "At-home" Titration of Solifenacin
NCT00759577 TERMINATED PHASE4
Validation of a Real-time Urodynamic Measure of Urinary Urgency
NCT00909428 COMPLETED PHASE4
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
NCT04641975 TERMINATED PHASE3
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
NCT03492281 COMPLETED PHASE3
Comparison of the Transcutaneous Tibial Nerve Stimulation and Drug Treatment' Effects in Women With Overactive Bladder
NCT06024005 COMPLETED NA